The pleiotropic cytokines interleukin (IL)-1 ␤ and tumor necrosis factor (TNF)-␣ have been implicated in the pathophysiology of asthma. To elucidate the role of these cytokines in the pro-asthmatic state, the effects of IL-1 ␤ and TNF-␣ on airway smooth muscle (ASM) responsiveness and ASM expression of multiple genes, assessed by high-density oligonucleotide array analysis, were examined in the absence and presence of the glucocorticoid dexamethasone (DEX). Administration of IL-1 ␤ /TNF-␣ increased ASM contractility to acetylcholine and impaired ASM relaxation to isoproterenol. These pro-asthmaticlike changes in ASM responsiveness were associated with IL-1 ␤ / TNF-␣ -induced mRNA expression of a host of proinflammatory genes that regulate transcription, cytokines and chemokines, cellular adhesion molecules, and various signal transduction molecules that regulate ASM responsiveness. In the presence of DEX, the changes induced in ASM responsiveness were abrogated, and most of the IL-1 ␤ /TNF-␣ -mediatied changes in proinflammatory gene expression were repressed, although mRNA expression of a small number of genes was enhanced by DEX. Collectively, the observations support the concept that, together with its role as a regulator of airway tone, in response to IL-1 ␤ /TNF-␣ , the ASM expresses a host of glucocorticoid-sensitive genes that contribute to the altered structure and function of the airways in the pro-asthmatic state. We speculate that glucocorticoid-sensitive, cytokine-induced pathways involved in ASM cell signaling represent important targets for new therapeutic interventions.
Altered airway responsiveness to bronchoactive constrictor and relaxant stimuli is the characteristic pathophysiologic feature of bronchial asthma (1) (2) (3) . Whereas infiltration of the airways with inflammatory cells, principally involving eosinophils, mast cells, and lymphocytes, is implicated in the etiology of the altered airway responsiveness, recent studies have determined that, under specific conditions, the airway smooth muscle (ASM) itself has the capacity to autologously induce changes in its constriction and relaxation in response to the induced release and autocrine actions of certain proinflammatory cytokines (4) (5) (6) (7) (8) (9) . Thus, IgE-dependent atopic sensitization and rhinovirus inoculation of ASM were shown to provoke the release of Th1-and Th2-type cytokines, IL-1 ␤ , and other cytokines from the ASM itself, and these cytokines acting alone or in combination were found to elicit pro-asthmatic changes in ASM responsiveness (4, 6, 10) . Moreover, in ultimately leading to altered ASM responsiveness, the autologous release of cytokines by ASM was found to display a pattern of sequential autocrine induction, as exemplified by an initial IL-5-mediated induction of the subsequent release of IL-1 ␤ in atopic sensitized and rhinovirus-inoculated ASM (5, 9) . Given this evidence and the fact that the altered ASM responsiveness is mechanistically channeled through the autocrine actions of IL-1 ␤ and, to a lesser extent, TNF-␣ (6, 11-13), the present study examined whether the latter pleiotropic cytokines exert an extended downstream effect in ASM by regulating the expression of other genes that may participate in the overall pro-asthmatic response. Accordingly, using high-density oligonucleotide array analysis, we examined the combined effects of IL-1 ␤ and TNF-␣ administration on ASM cell expression of genes encoding a variety of cytokines, cellular adhesion molecules (CAMs), transcription factors, and other cell-signaling molecules potentially associated with the regulation of ASM responsiveness. Moreover, in an attempt to further elucidate those genes that may contribute to pro-asthmatic changes in ASM responsiveness, we examined the effects of glucocorticoid treatment on ASM responsiveness and its associated pattern of altered gene expression in ASM cells exposed to IL-1 ␤ and TNF-␣ . The rationale for using this strategy was based on the well established efficacy of glucocorticoids in the amelioration of asthma symptoms and altered responsiveness in asthmatic airways (14) (15) (16) as well as the ability of glucocorticoids to generally attenuate the expression of proinflammatory genes (7, (17) (18) (19) . The results provide new evidence demonstrating that ( i ) IL-1 ␤ and TNF-␣ induce pro-asthmatic-like changes in ASM responsiveness in association with upregulated mRNA expression of a host of genes encoding cytokines, CAMs, transcription factors, and other cell-signaling molecules; ( ii ) the induced changes in ASM responsiveness are prevented by pretreating the ASM with the glucocorticoid dexamethasone; and ( iii ) the latter protective effect on ASM responsiveness is associated with glucocorticoid-induced modulation of expression of a number of upregulated genes. Collectively, these findings provide new insights into those glucocorticoid-sensitive genes expressed by ASM which are coupled to pro-asthmatic changes in ASM responsiveness.
Materials and Methods

Animals
Ten adult New Zealand White rabbits were used in this study, which was approved by the Biosafety and Animal Research Committee of the Joseph Stokes Research Institute at Children's Hospital of Philadelphia. The animals had no signs of respiratory disease before the study.
Preparation of ASM Tissues
After anesthesia with xylazine (10 mg/kg) and ketamine (50 mg/kg), the animals were killed with systemic air embolism. The tracheas were removed via open thoracotomy, cleared of loose connective tissue, divided into eight ring segments of 6-8 mm in length, and incubated for 18 h at room temperature in Dulbecco's modified Eagle's medium containing both IL-1 ␤ (10 ng/ml) and TNF-␣ (100 ng/ml) or in medium alone with no added cytokines, both conditions in the absence and presence of dexamethazone (DEX; 10 Ϫ 5 M). The medium was aerated with a continuous supplemental O 2 mixture (95% O 2 /5% CO 2 ) during the incubation phase.
Pharmacodynamic Studies
After incubation, the cytokine-and DEX-treated issues were repeatedly rinsed, and each airway segment was suspended longitudinally between stainless steel triangular supports in siliconized 20-ml organ baths (Harvard Apparatus, South Natick, MA). The lower support was secured to the base of the organ bath, and the upper support was attached via a gold chain to a force transducer (FT.03C; Grass Instruments, Quincy, MA) from which isometric tension was continuously displayed on a multichannel recorder. Care was taken to place the membranous portion of the trachea between the supports to maximize the recorded tension generated by the contracting trachealis muscle. The tissues were bathed in modified Krebs-Ringer solution containing (in mM) 125 NaCl, 14 NaHCO 3 , 4 KCl, 2.25 CaCl 2 ·2H 2 O, 1.46 MgSO 4 ·7H 2 O, 1.2 NaH 2 PO4·H 2 O, and 11 glucose. The baths were aerated with 5% CO 2 in oxygen, a pH of 7.35-7.40 was maintained, and the temperature was held at 37 Њ C. Passive resting tension of each tracheal smooth muscle segment was set at 2.0 g after each tissue had been passively stretched to a tension of 8 g to optimize the resting length, as previously described (20) . The tissues were allowed to equilibrate in the bath for 45 min, at which time each tissue was primed with a 1-min exposure to 10 Ϫ 4 M acetylcholine (ACh). Cholinergic contractility was initially assessed in the ASM by cumulative administration of ACh in final bath concentrations ranging from 10 Ϫ 9 to 10 Ϫ 3 M. Thereafter, following thorough rinsing, each tissue segment was half-maximally contracted with ACh, and relaxation dose-response relationships to cumulative administration of isoproterenol (10 Ϫ 9 to 10 Ϫ 4 M) were generated in paired IL-1 ␤ /TNF-␣ -treated and control tissues in the absence or presence of cotreatment with DEX. The initial constrictor dose-response curves to ACh were analyzed in terms of maximal isometric contractile force (Tmax) and sensitivity to the agonist, expressed as the negative logarithm of the concentration of ACh producing 50% of Tmax (pD50; i.e., geometric mean ED50 value). The relaxant responses to isoproterenol were analyzed in terms of percent maximal relaxation (Rmax) from the active cholinergic contraction, and sensitivity to the relaxing agent was determined as the corresponding pD50 value associated with 50% of Rmax.
Assessment of Gene Microarray Expression
Simultaneous expression of mRNA from multiple genes was examined in human ASM cells with the Affymetrix (Santa Clara, CA) expression microarray system using human gene chips (HUGeneFL array) representing ‫ف‬ 5,000 genes. The ASM cells were derived from a 21-yr-old male donor (Clonetics, San Diego, CA) who had no evidence of pulmonary disease, and the cells were carefully characterized by the manufacturer with specific markers to confirm their selective smooth muscle phenotype and to exclude contamination with other cell types. The cells were maintained at 37 Њ C in a humidified atmosphere of 5% CO 2 /95% air and grown in a mixture of 5% Smooth muscle Basal Medium, which was supplemented with 10% fetal bovine serum, insulin (5 ng/ml), epithelial growth factor (10 ng/ml; human recombinant), fibroblast growth factor (FGF) (2 ng/ml; human recombinant), gentamycin (50 ng/ml), and amphotericin-B (50 ng/ml), as previously described (4) (5) (6) . Once the cells had reached ‫ف‬ 95% confluence, they were exposed for 4 h to IL-1 ␤ (1 ng/ml) and TNF-␣ (5 ng/ml) combined, or to media alone in the absence and presence of 1 h pretreatment with DEX (10 Ϫ 5 M). Four experiments were separately performed from this same primary cell line, at passages 6-8.
Following incubation of the cells, the total RNA used for the Affymertrix microarray expression analysis was extracted and purified using commercially available reagents and in accordance with methods recommended by the manufacturer (21) . Briefly, total RNA was extracted using Trizol and purified with Qiagen RNaeasy spin columns. Approximately 5 g of RNA was used for first-and second-strand cDNA synthesis. After precipitation, the cDNAs were transcribed to cRNAs. Four cRNA reactions were separately performed, one from each experimental culture. The biotinylated cRNA was subsequently hybridized to the Affymetrix gene chips overnight. Nonbound probes were removed by stringency washing. The hybridized chips were developed using a Streptavidin-Phycoerythrin complex and scanned. The scanned images were then analyzed with Affymetrix software, and the data were examined using commercially available software, including Spotfire Net 5.1 (Spotfire, Somerville, MA) (22) . The gene expression values were automatically subtracted from background levels, which were calculated by dividing the array into 16 sectors wherein the average of the lowest 2% of intensity in each sector is used as background for genes within that sector. The background was then subtracted from the average difference intensity values. The human 6800K gene array also contains two probe sets (actin and glyceraldehyde phosphate dehydrogenase) in sense direction to control for DNA contamination. For the set of chips used, the average signal for the genes scored as absent is approximately 30 (21) . In this study, to avoid errors due to low copy numbers, genes with average difference expression less than 70 were scored as absent. Baseline expression values for all genes included their average difference expression at the 0-h time point for genes with average difference values above 70.
Statistical Analysis
Unless otherwise indicated, results are expressed as means Ϯ SE. Statistical analysis was performed using two-tailed paired Student's t test or ANOVA with multiple comparisons of means, where appropriate. P values Ͻ 0.05 were considered significant. The standard errors for the gene array experiments were calculated for each gene from the four separate experiments using a commercially available statistical software program from GraphPad (GraphPad Software, San Diego, CA).
Reagents
The DNA oligonucleotide HuGeneFL chips and analysis system, including scanner and computer analysis software, were purchased from Affymetrix. Human ASM cells were purchased from Clonetics (San Diego, CA). Dulbecco's modified Eagle's medium Trizol and cDNA synthesis kits were purchased from Gibco BRL (Gaithersburg, MD). IL-1 ␤ and TNF-␣ were obtained from R&D Systems (Minneapolis, MN). RNA purification spin columns were obtained from Qiagen (Qiagen Inc., Valencia, CA). The in vitro transcription kit was obtained from Affymetrix. Streptavidin Phycoerythrin was purchased from Molecular Probes (Leiden, the Netherlands). ACh, isoproterenol hydrochloride, and dexamethasone were purchased from Sigma Chemical (St. Louis, MO). All drug concentrations are expressed as final bath concentrations. Isoproterenol and ACh were made fresh for each experiment, dissolved in normal saline to prepare 10 Ϫ 4 M and 10 Ϫ 3 M solutions, respectively.
Results
Effects of IL-1 ␤ and TNF-␣ on ASM Responsiveness
ASM constrictor dose-response relationships to ACh were determined in tissues preincubated for 24 h in medium alone and in the presence of maximally effective concentrations of IL-1 ␤ and TNF-␣ (11). As shown in Figure 1 , relative to controls, the IL-1 ␤ /TNF-␣ -treated tissues responded to ACh by constricting significantly more than the control tissues, with mean Ϯ SE values for Tmax amounting to 119.4 Ϯ 14.5 g/g ASM weight in the IL-1 ␤ /TNF-␣ -treated ASM but 93.7 Ϯ 8.9 in the control ASM ( P Ͻ 0.01). Additionally, constrictor sensitivity to ACh was relatively enhanced in the cytokine-treated tissues, with mean Ϯ SE values for pD50 (i.e., Ϫ log ED50) amounting to 4.95 Ϯ 0.06 Ϫ log M in the IL-1 ␤ /TNF-␣ -treated ASM but 4.66 Ϯ 0.12 in the control ASM ( P Ͻ 0.05).
In separate studies, during comparable levels of initial sustained ACh-induced contractions, averaging ‫ف‬ 50% of Tmax, ASM relaxation responses to cumulative administration of the ␤ -adrenergic agonist isoproterenal were generated in control and IL-1 ␤ /TNF-␣ -treated tissues. As shown in Figure 2 , relative to controls, the Rmax responses and pD50 values for isoproterenol were significantly attenuated in the IL-1 ␤ /TNF-␣ -treated tissues. Accordingly, the Rmax values amounted to 41.3 Ϯ 6.0% in the cytokinetreated ASM and 57.7 Ϯ 7.1% in the control ASM ( P Ͻ 0.01), and the corresponding pD50 values amounted to 5.87 Ϯ 0.05 and 6.09 Ϯ 0.11 Ϫ log M, respectively ( P Ͻ 0.05).
Effects of IL-1 ␤ /TNF-␣ on ASM Cell Gene Expression
In light of the above observations, to uncover gene pathways associated with IL-1 ␤ /TNF-␣-induced changes in ASM responsiveness, we examined in cultured human ASM cells the effects of these cytokines on mRNA expression of multiple genes putatively involved in various cell-signaling processes in ASM. Using a high-density oligonucleotide DNA microarray analysis, we found in four separate experiments that ‫ف‬ 40% of genes were expressed in untreated ASM cells and that treatment of cells with IL-1␤/ TNF-␣ did not significantly alter the total number of genes expressed. More than 400 genes, however, demonstrated up-or downregulation of their mRNA signals in response to IL-1␤/TNF-␣ administration. Given the established sensitivity of the expression technique applied (21), a 2-fold increase in signal intensities from baseline was considered significant. Accordingly, ‫ف‬ 70 genes that play a potential role in cell signaling in ASM demonstrated a у 2-fold (i.e., 2 to ‫ف‬ 150-fold) increase in mRNA expression in response to IL-1␤/TNF-␣. The latter collection of genes is categorically displayed in Figures 3-6 with the genes in each category identified by their symbols and Gene Bank accession numbers and plotted in relation to their respective magnitudes (mean Ϯ SE values of fold-increase) of altered mRNA expression.
Within the cytokine/chemokine category of genes, those depicting upregulated mRNA expression by an average of у 10-fold above baseline in response to IL-1␤/TNF-␣ included the small inducible cytokine subfamily B (SCYB) members -2, -3, -1, -5, and -6, IL-1␤, IL-8, colony-stimulating factor (CSF)-2 (i.e., GM-CSF), TNF-␣IP3, IL-6, and CSF-3 ( Figure 3 ). Within the CAM/extracellular matrix (ECM)-related category of genes, those upregulated у 10-fold included ICAM-1, matrix metalloproteinase (MMP)-12, and VCAM-1 (Figure 4) , and, within the category of transcription factors, the genes comparably upregulated included NR4A3 and BCL-2A1 ( Figure 5 ). Other genes related to various aspects of cellular signaling/metabolism, including those encoding various proteases, kinases, and other molecules involved in signal transduction were also upregulated in ASM cells in response to IL-1␤/TNF-␣ administration, most notably including phosphodieseterase (PDE)D4, superoxide dismutase-2, and inducible cyclooxygenase (COX)-2 ( Figure 6 ). Contrasting these observations, treatment of cells with IL-1␤/TNF-␣ had no effect on mRNA expression of constitutively expressed "housekeeping" genes such as ␤-actin, ribosomal protein L7, ␤2-microglobulin, and others (data not shown; available on website).
Glucocorticoid Effect on IL-1␤/TNF-␣-Induced Changes in ASM Responsiveness
To assess whether the IL-1␤/TNF-␣-induced changes in ASM responsiveness are glucocorticoid sensitive, contractile dose-response relationships to ACh were compared between IL-1␤/TNF-␣-treated ASM tissues and their respective paired control ASM segments, both in the absence and presence of pretreatment of the tissues for 60 min with dexamethasone (DEX; 10 Ϫ5 M). As shown in Figure 7 , the heightened constrictor responses to ACh generated in IL-1␤/TNF-␣-exposed ASM were abrogated by pretreating the cytokine-exposed tissues with DEX. Accordingly, in these DEX-pretreated tissues, the mean Ϯ SE Tmax and pD50 values were 102.9 Ϯ 13.1 g/g ASM weight and 4.89 Ϯ 0.05 Ϫlog M, respectively, and the latter determinations were similar to those obtained in control ASM. In contrast, pretreatment with DEX had no effect on the constrictor responses to ACh in control tissues ( Figure 7 , open squares).
Comparable to the protective effects of DEX on cytokine-induced changes in ASM constrictor responsiveness, the impaired ␤-adrenoceptor-mediated relaxation responses to isoproterenol obtained in IL-1␤/TNF-␣-exposed ASM were also completely abrogated by pretreating the tissues with DEX (Figure 8 ). Accordingly, in these DEX-pretreated tissues, the mean Rmax and pD50 values for iso- proterenol averaged 55.5 Ϯ 5.7% and 5.99 Ϯ 0.06 Ϫlog M, respectively, and the latter determinations were similar to those obtained in control ASM. In contrast, pretreatment with DEX had no effect on the relaxation responses to isoproterenol in control tissues (Figure 8, open squares) .
Corticosteroid Effect on IL-1␤/TNF-␣-Induced Gene Expression in ASM Cells
Given the efficacy of DEX in ablating the effects of IL-1␤/ TNF-␣ on ASM responsiveness, we next examined whether DEX also modulates the above-mentioned effects of IL-1␤/ TNF-␣ on multiple gene expression in ASM cells. In these experiments, paired cultures of ASM cells were exposed to vehicle alone (control) or to IL-1␤/TNF-␣ in the absence or presence of DEX (10 Ϫ5 M) with each condition examined in duplicate. For a given gene, sensitivity to DEX was then determined as the ratio of the altered (fold-change) mRNA levels elicited by IL-1␤/TNF-␣ in the presence and absence of DEX. Accordingly, a mRNA expression ratio (MER) of 1.0 implied a lack of effect of DEX, whereas MER values below and above 1.0 denoted DEX-induced repression and stimulation of mRNA expression, respectively. The results demonstrate that the upregulated mRNA levels exhibited by cells exposed to IL-1␤/TNF-␣ were largely repressed by pretreating the cells with DEX, as evidenced by MER values below 1.0 for the majority of genes belonging to each category ( Figure 9 ). Not all genes, however, displayed DEX sensitivity, and, as shown in Figure 9 , a small number of genes in each category exhibited stimulation of IL-1␤/TNF-␣-induced mRNA expression in the presence of DEX (i.e., MERs Ͼ 1.0). In evaluating the variability in DEX sensitivity within each category of genes, we found no correlation between the MER values for the different genes and their corresponding magnitudes of IL-1␤/TNF-␣-induced enhanced mRNA expression in the absence of DEX. Of the DEX-sensitive genes depicted in Figure 9 , those that exhibited у 10% DEX-induced decrease in mRNA expression (i.e., MER values р 0.90) are identified in Table 1. It is noted that a strong repressive effect of DEX was seen for genes known to be involved in the regulation of cAMP and Ca 2ϩ mobilization, including the phosphodiesterase D4 and plasma membrane Ca 2ϩ ATPase genes, which provided MER values of 0.40 and 0.34, respectively, corresponding to 60 and 66% inhibition of IL-1␤/TNF-␣-induced mRNA expression in the presence of DEX, respectively. Additionally, certain cytokine/chemokine-related and other cell signaling-related genes were also significantly inhibited by DEX, including the pro-IL-1␤, IL-8, IL-13R, small inducible SCY-B2, -B6, -A7, bradykinin receptor-2, and COX-2 genes. Moreover, it is relevant to note that the p50-NF-B gene, which belongs to the NF-B family of inducible transcription factors that regulate the host immune and inflammatory responses, was inhibited by 51% by DEX (i.e., MER ϭ 0.49). Finally, MMP3 and, most notably, MMP10 and MMP12 genes, which are implicated in tissue remodeling, were also markedly inhibited by DEX.
Among the collection of DEX-sensitive genes exhibiting у 10% augmentation of IL-1␤/TNF-␣-induced mRNA expression (i.e., MER values у 1.10), as shown in Table 2 , those belonging the cell signaling-related category included 11-␤-hydroxysteroid-dehydroxgenase-1, the MAP kinase subtype, MAPKKK5, and the ATP-binding cassette gene, ABC-B2. In the cytokine/chemokine-related category, DEXinduced augmented mRNA expression was most evidenced by genes encoding epithelial-derived neutrophil-activating peptide 78 (SCYB5), colony (granulocyte) stimulating factor 3 (CSF3), TNF-␣-induced protein 3 (TNF-␣-IP3), and TNF-␣-IP6. Finally, other genes upregulated by DEX included the transcription factor-related gene, CCAATenhancer binding protein-delta, and the CAM/ECM molecule-related gene, tenascin C. Ϫ5 M. Data represent means Ϯ SE from six paired experiments. Note: Relative to tissues incubated with vehicle alone, both the Tmax and pD50 responses to ACh were significantly enhanced in ASM segments that were exposed to IL-1␤/TNF-␣, whereas the latter effects on the Tmax and pD50 values were largely prevented by pretreating the ASM tissues with dexamethasone (P Ͻ 0.01 and P Ͻ 0.05, respectively). In contrast, treatment with dexamethasone 10 Ϫ5 M alone (open squares), had no effect on either the Tmax or ED50 responses to ACh. Ϫ5 M. Data represent means Ϯ SE from six paired experiments. Note: Relative to tissues incubated with vehicle alone, both the Rmax and pD50 responses to isoproterenol were significantly attenuated in ASM segments that were exposed to IL-1␤/TNF-␣, whereas the latter effects on the Rmax and pD50 values were largely prevented by pretreating the ASM tissues with dexamethasone (P Ͻ 0.01 and P Ͻ 0.05, respectively). In contrast, treatment with dexamethasone 10 Ϫ5 M alone (open squares), had no effect on either the Rmax or pD50 responses to isoproterenol. 
Discussion
The pleiotropic cytokines IL-1␤ and TNF-␣ have been implicated in the pathophysiology of a host of proinflammatory disorders, including bronchial asthma. Regarding the latter, elevated levels of these cytokines have been detected in the bronchoalveolar lavage fluid from asthmatic patients (23) (24) (25) , and both IL-1␤ and TNF-␣ have been implicated in the development of airway constrictor hyperresponsiveness in animal models of allergic asthma (26, 27) . Furthermore, in a series of recent studies, we have shown that IL-1␤ and, to a somewhat lesser extent, TNF-␣, act directly on ASM to produce pro-asthmatic-like changes in ASM responsiveness (6, 11), a phenomenon mechanistically coupled to induced upregulated expression and action of G i protein, which inhibits cAMP accumulation in ASM (11, 20) . Given this evidence, together with other findings demonstrating that the induction of pro-asthmatic changes in ASM responsiveness by atopic sensitization (IgE-mediated) of ASM or rhinovirus inoculation of ASM is mechanistically channeled through the autocrine release and actions of IL-1␤ and TNF-␣ in the ASM itself (10, 28, 29) , this study examined whether these cytokines exert an ex- Genes are identified by their gene symbols and Gene Bank accession numbers. The MER value given for each gene refers to the ratio of mRNA expression levels elicited by IL-1␤/TNF-␣ in the presence and absence of dexamethasone.
tended downstream effect in ASM by regulating the expression of other putative genes participating in the overall pro-asthmatic response in ASM. Using high-density gene microarray technology for simultaneous analysis of multiple gene expression in a high-throughput fashion, our results demonstrated that (i) in association with induced pro-asthmatic-like changes in ASM responsiveness, IL-1␤/ TNF-␣-exposed ASM cells exhibited altered mRNA expression of more than 400 genes, of which ‫ف‬ 70 genes involved with various aspects of cell signaling were upregulated by у 2-fold; (ii) of the latter collection of genes stimulated by IL-1␤/TNF-␣, the majority were inhibited by cotreatment of ASM cells with dexamethasone, in association with ablation of the pro-asthmatic effects of IL-1␤/ TNF-␣ on ASM responsiveness by the glucocorticoid; and (iii) a minority of genes modulated by IL-1␤/TNF-␣ were upregulated in the presence of dexamethasone. Collectively, these observations show that IL-1␤/TNF-␣ elicits glucocorticoid-sensitive pro-asthmatic-like changes in ASM responsiveness, which are associated with glucocorticoidsensitive modulation of proinflammatory gene expression patterns in ASM that potentially contribute to the altered airway structure and function in asthma.
Treatment of ASM tissues with the combination of IL-1␤ and TNF-␣ elicited pro-asthmatic-like changes in ASM responsiveness, including heightened constrictor responsiveness to cholinergic stimulation ( Figure 1 ) and impaired relaxation to ␤-adrenoceptor stimulation (Figure 2) (11) . We previously determined that these actions of IL-1␤ and TNF-␣ are associated with an induced upregulated expression and action of G i protein, principally involving G i ␣2 and G i ␣3, which inhibit ␤-adrenoceptor-mediated cAMP accumulation (6, 11, 20) . Interestingly, the present results demonstrated that, among the collection of cell-signaling/ metabolism genes expressed by ASM cells, mRNA expression of a number of genes known to regulate smooth muscle contractility and relaxation was significantly upregulated in response to IL-1␤/TNF-␣ ( Figure 6 ). Accordingly, phosphodiesterase (PDE)-4B, which acts in ASM cells to inhibit cAMP accumulation (30, 31) , was most markedly upregulated in the presence of IL-1␤/TNF-␣, suggesting the induction of an extended mechanism of attenuated cAMP accumulation (i.e., downstream to G i protein activation) accompanying the pro-asthmatic-like changes in ASM responsiveness. The relevance of the latter mechanism is supported by the findings described in a recent report that inhibition of PDE-4 largely ablates the airway constrictor hyperresponsiveness and airway inflammation in an in vivo murine model of allergic asthma (32, 33) . In addition to PDE-4, our results also identified IL-1␤/TNF-␣-induced upregulated mRNA expression of certain genes regulating intracellular Ca 2ϩ levels, including plasma membrane Ca 2ϩ -ATPase (i.e., ATP2B1), stanniocalcin-1 (i.e., STC1), and others. Moreover, upregulated mRNA expression was also displayed by a host of proinflammatory genes that may further contribute to the observed changes in ASM responsiveness. These include COX-2 ( Figure 6 ), as well as various cytokine/chemokine genes ( Figure 3 ) that have been previously implicated in the allergic asthmatic state, such as IL-8, CSF-2 (GM-CSF), IL-6, RANTES, various numbers of the small inducible cytokine SCYB, and others. Thus, downstream to activation with IL-1␤ and TNF-␣, ASM cells upregulated mRNA expression of a pattern of proinflammatory genes in association with the induction of proasthmatic changes in ASM responsiveness. Whereas the relative contributions of these individual or combined changes in cytokine/chemokine gene expression remain to be elucidated, given the diverse proinflammatory nature of these genes, it is reasonable to speculate that, beyond inducing autologous changes in its responsiveness through autocrine mechanisms, the ASM may also act as a paracrine source for the activation of other cell types (e.g., leukocytes) contributing to the overall proinflammatory asthmatic state. Within the category of genes expressing CAM/ECM molecules, the pronounced upregulation of ICAM-1 mRNA following exposure of ASM cells to IL-1␤/TNF-␣ ( Figure  4 ) is consistent with previous findings demonstrating increased ICAM-1 expression and signaling in ASM exposed to atopic asthmatic serum (34) and to rhinovirus (35) , conditions that are both associated with the induction of pro-asthmatic changes in ASM responsiveness (36) . Moreover, in accordance with the present observations ( Figure  4 ), enhanced expression of various extracellular matrix metalloproteinases has also been demonstrated in asthmatic airways and lungs (37, 38) , as well as in various animal models of allergic asthma (39) . To the extent that IL-1␤ and TNF-␣ have been shown to induce ASM cell proliferation (40) , a phenomenon associated with altered expression and function of specific matrix metalloproteinases (41), the present observations lend further support to the notion that the ASM itself may autologously regulate its own state of proliferation under pro-asthmatic conditions (37) (38) (39) (40) (41) . This notion is consistent with our observation that IL-1␤/TNF-␣-induced upregulated mRNA expression of various transcription factors ( Figure 5 ) associated with altered cellular proliferation and differentiation (e.g., BCL-2A1, STAT5A, p50-NF-B, NFATC1, etc.). Taken together, these results concur with recent evidence demonstrating an autocrine role for the ASM in the overall process of airway remodeling in the asthmatic state (42) .
The observed ability of dexamethasone to abrogate IL-1␤/TNF-␣-induced changes in ASM constrictor (Figure 7 ) and relaxant responsiveness (Figure 8 ) parallels the known efficacy of glucocorticoids both in the treatment of asthma and attenuation of the altered bronchial responsiveness associated with this disease (15) (16) (17) (18) . Moreover, in accordance with the inherent antiinflammatory properties of glucocorticoids, our results demonstrate that DEX represses the upregulated mRNA expression displayed by a majority of genes stimulated in the presence of IL-1␤/ TNF-␣ (Figure 9 ). Accordingly, with the exception of tenascin C (i.e., HXB), all the other genes belonging to the CAM/ECM molecules category were suppressed to varying extents by DEX (Table 1) . Most genes belonging to the cytokines/chemokines category were also repressed by DEX, notably including IL-1␤, RANTES, IL-8, IL-6, IL-13 receptor-␣, members of the small inducible cytokine (SCY) subfamilies A and B, and others (Table 1) . Moreover, within the cell-signaling/metabolism category, it is relevant to note that DEX markedly repressed the IL-1␤/ TNF-␣-induced expression of genes associated with altered cAMP metabolism (e.g., PDE-4B and AMPD3) and Ca 2ϩ mobilization and homeostasis (e.g., ATP2B1 and STC1). Finally, IL-1␤/TNF-␣-induced changes in mRNA expression of most genes in the transcription category were inhibited by DEX, notably including BCL2A1, NP4A3, p50-NF-B, and NFATC1. An important consideration raised by the latter observed effect of DEX relates to the crucial roles played by these transcription factors as regulators of the host immune and inflammatory responses, as well as critical aspects of cellular proliferation and apoptosis. For example, with respect to p50-NF-B, the latter has been implicated in the regulation of cellular expression of genes encoding nearly 30 different cytokines and chemokines, receptors involved in immune recognition, T-and B-cell differentiation, apoptosis, cellular adhesion molecules, and such proinflammatory enzymes as inducible cyclooxygenase (COX-2) (43) (44) (45) . Similarly, the transcription factor NFAT-C1 participates in the transactivation of a number of cytokine genes (46, 47) , and its induction by growth factors in vascular smooth muscle cells (VSMC) has been implicated in such processes as extracellular matrix remodeling and VSMC growth (48) . Given this evidence, in light of our present observations, it may be argued that the overall pattern of induced proinflammatory gene expression in response to IL-1␤/TNF-␣ administration was attributed to the known stimulatory actions of these cytokines on certain inducible transcription pathways (49) and that the overall repressive effect of DEX on the collection of proinflammatory genes was attributed to the known inhibitory effect of the glucocorticoid on various inducible transcription factors, most notably including NF-B (50) .
Whereas DEX repressed the enhanced mRNA expression of most genes upregulated by IL-1␤/TNF-␣, mRNA levels of a relatively smaller number of genes were unaffected or augmented in the presence of DEX (Table 2) . Interestingly, the observed stimulatory effect of DEX was displayed by several genes belonging to the cytokines/chemokines category, specifically including SCYB-5, CSF-3, and TNF-␣IP6. The observed enhanced mRNA expression of these genes was somewhat unexpected, given their known proinflammatory roles. Although the mechanism underlying this effect is not readily explained, it is relevant to note that, in addition to binding to its DNA glucocorticoid-response element, the activated glucocorticoid receptor is also known to interact and cooperate positively with certain transcription factors that regulate the expression of various proinflammatory genes, including STAT3, STAT5, OCT, and AP-1 (51-53). Thus, despite the well established overall antiinflammatory properties of glucocorticoids, the latter may upregulate the expression of certain proinflammatory genes. The extent to which this action of glucocorticoids serves to modulate airway function in the asthmatic state remains to be elucidated, although it is likely that the therapeutic efficacy of glucocorticoids in the treatment of asthma is given by the net result of their suppressive action on proinflammatory gene expression (see Table 1 ) and upregulation of other genes potentially regulating airway structure and function (see Table 2 ). In addition, other factors, such as altered mRNA stability and mRNA transport critical to its translation, may, at least in part, explain the failure of DEX to reverse mRNA levels for a number of genes. These factors are currently being systematically addressed in new and extended experiments.
An important issue related to the above collection of present findings is that our observations on the effects of IL-1␤/TNF-␣ administration and dexamethasone treatment were based on studies conducted using rabbit ASM tissues and cultured human ASM cells. Whereas the experiments using these different preparations provided results that were largely complimentary in nature, the issue of potential species differences warrants consideration. In this regard, it is relevant to note that earlier studies using atopic asthmatic serum sensitization and rhinovirus exposure to elicit pro-asthmatic-like changes in ASM responsiveness have reported comparable effects of these treatment conditions in rabbit and human ASM cells and tissues. Accordingly, atopic asthmatic serum sensitization was found to elicit qualitatively similar upregulated expression of the low affinity receptor for IgE, FcRII (i.e., CD23), in both rabbit and human ASM cells (28, 29) , as well as increased release of IL-1␤ from both cell types (6, 29) . Moreover, rhinovirus inoculation of rabbit and human ASM cells was also found to provoke the release of IL-␤ from both cell types (5, 10) . Thus, collectively, the findings from these earlier reports, together with those of the present study, suggest that there exists a good concordance between rabbit and human ASM cells, at least with respect to the role of IL-1␤ in regulating ASM function. Finally, although it remains to be established whether such an interspecies concordance also exists in vivo, it is noteworthy that, in general agreement with the present in vitro observations, in vivo administration of an IL-1 receptor antagonist in a guinea pig model of allergic asthma was shown to prevent allergen-induced pro-asthmatic-like changes in airway responsiveness, as well as the accompanying pulmonary infiltration with eosinophils (26) .
Another issue pertaining to the present observations relates to our use of different durations of exposure to IL-1␤/ TNF-␣ and DEX to determine the effects of these agents on gene array expression in the cultured ASM cells and agonist responsiveness in the ASM tissues. In this regard, changes in ASM agonist responsiveness were examined after exposure of tissues for 18 h to the different treatment conditions, whereas a shorter treatment duration of 4 h was used in the gene array experiments. Our use of these different treatment durations was based on results obtained in previous studies wherein we determined the differences in duration needed for effective induction of acute changes in mRNA expression and resultant alterations in ASM tissue agonist responsiveness (6, 11) . In this context, the extended duration needed to evoke changes in ASM tissue responsiveness likely reflects the time required for effective translation of altered mRNA levels into proteins ultimately responsible for the observed changes in tissue agonist responsiveness. Notwithstanding this consideration, an extended systematic evaluation of the effects of varying durations of exposure to IL-1␤/TNF-␣ and DEX on gene array expression in ASM warrants future investigation.
In conclusion, using the high-density cDNA microarray technique, in this study we investigated the pattern of altered expression of multiple genes by ASM cells induced downstream to activation with IL-1␤/TNF-␣ and examined how this induced profile of gene expression is modulated by glucocorticoid treatment. This study demonstrated that, in association with pro-asthmatic-like changes in ASM responsiveness elicited by IL-1␤/TNF-␣, these cytokines induced upregulated mRNA expression of a host of proinflammatory genes that regulate gene transcription, cytokines and chemokines, cellular adhesion molecules, and other signal transduction molecules that regulate ASM responsiveness. Moreover, in addition to suppression of the IL-1␤/TNF-␣-induced changes in ASM responsiveness by the glucocorticoid, dexamethasone, the latter repressed most of the IL-1␤/TNF-␣-induced changes in proinflammatory gene expression, whereas a small number of genes were further upregulated by dexamethasone. Collectively, these findings support the concept that, together with its role as a regulator of airway tone, the ASM is capable of expressing a host of glucocorticoid-sensitive proinflammatory genes that may contribute to the altered structure and function of the airways in the pro-asthmatic state. Extended studies are needed to elucidate the role of this inducible pattern of multiple gene expression by the ASM in the overall pathobiology of asthma.
